Navigation Links
BioMarin to Present at the Goldman Sachs Healthcare Conference
Date:6/2/2009

NOVATO, Calif., June 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Goldman Sachs 30th Annual Global Healthcare Conference in New York City on Tuesday, June 9, 2009 at 9:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 is ... on the global resorcinol industry. The report highlights the various growth prospects and ... and analysis of primary and secondary inputs from the existing players of the ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Surveillance System Detects ... Emerging Pattern, ... hours,on a recent Friday, 20 people arrived, one by one, for ... various,gastrointestinal symptoms, including nausea and diarrhea., A coincidence? Or the ...
... CHAPEL HILL, N.C., May 22 Pharmaceutical and biotech,companies ... Assurance (QA) functions. This benchmarking study will help R&D,Quality ... Optimizing limited QA staff resources so that they have ... Optimizing services in regards to the FDA,s Risk-Bases method ...
... investor ... conference call, ... of BioElectronics Corporation (Pink Sheets: BIEL), the,developer of ActiPatch, an ... delivers pulsed,electromagnetic therapy, today issued the following summary of its ...
Cached Biology Technology:E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 3BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 4BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 5BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 6BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 7BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 8
(Date:7/23/2015)... DUBLIN , July 23, 2015 ... the addition of the "Global Outlook of ... their offering. The global biometrics ... both public and commercial applications owing to the ... will witness a transformation that enhances the growth ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... is available in French . , Montreal, November ... poisoning, may be a thing of the past. New findings ... Institute for Agronomic Research (INRA), involving the Universit de Montral ... bacterium is able to survive in the competitive environment ...
... WALTHAM, MA November 28, 2010 ... targeted covalent drugs, has published research in ... irreversible inhibition of a viral protease using a ... "Selective Irreversible Inhibition of a Protease by Targeting ...
... the Advancement of Science has chosen Arizona State University,s ... education, to receive the Science Prize for ... prize, established to "encourage innovation and excellence in education, ... by students, teachers, and the public," recognizes the website,s ...
Cached Biology News:Will this be the end of hamburger disease? 2First-ever covalent irreversible inhibition of a protease central to hepatitis C infection 2ASU’s Ask A Biologist website wins prestigious SPORE prize 2ASU’s Ask A Biologist website wins prestigious SPORE prize 3
... ZMD.414. Immunogen: Synthetic peptide derived from ... rat mTOR (Mammalian target of rapamycin FRAP ... human mTOR protein. On Western blots ... kDa. Reactivity: Human (positive control: HEK293 ...
MW5...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: